WO2006060533A3 - Conjugues medicament anticorps et procedes correspondants - Google Patents

Conjugues medicament anticorps et procedes correspondants Download PDF

Info

Publication number
WO2006060533A3
WO2006060533A3 PCT/US2005/043409 US2005043409W WO2006060533A3 WO 2006060533 A3 WO2006060533 A3 WO 2006060533A3 US 2005043409 W US2005043409 W US 2005043409W WO 2006060533 A3 WO2006060533 A3 WO 2006060533A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
adc
formula
relates
bis
Prior art date
Application number
PCT/US2005/043409
Other languages
English (en)
Other versions
WO2006060533A2 (fr
Inventor
Lewis J Gazzard
Edward Hyungsuk Ha
David Y Jackson
Joann Um
Original Assignee
Genentech Inc
Lewis J Gazzard
Edward Hyungsuk Ha
David Y Jackson
Joann Um
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Lewis J Gazzard, Edward Hyungsuk Ha, David Y Jackson, Joann Um filed Critical Genentech Inc
Priority to JP2007544495A priority Critical patent/JP4993645B2/ja
Priority to EP05852595A priority patent/EP1817059A2/fr
Publication of WO2006060533A2 publication Critical patent/WO2006060533A2/fr
Publication of WO2006060533A3 publication Critical patent/WO2006060533A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

L'invention concerne des composés conjugués de médicament anticorps (antibody drug conjugate -ADC) représentés par la formule (I) où au moins des fractions médicement 1,8 bis-naphthalimide (D) ayant les formules (IIa) et (Ilb) sont liées par covalence à un anticorps (Ab) par un lieur (L). L'invention concerne également des compositions pharmaceutiques ayant une quantité efficace d'un ADC de la formule (I) pour le traitement de troubles hyperprolifératifs et autres troubles. L'invention concerne également des procédés permettant de tuer ou d'inhiber la multiplication d'une cellule tumorale ou d'une cellule cancéreuse comportant l'administration à un patient d'une quantité efficace d'un ADC de formule (I).
PCT/US2005/043409 2004-12-01 2005-11-29 Conjugues medicament anticorps et procedes correspondants WO2006060533A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007544495A JP4993645B2 (ja) 2004-12-01 2005-11-29 抗体薬剤結合体および方法
EP05852595A EP1817059A2 (fr) 2004-12-01 2005-11-29 Conjugues medicament anticorps et procedes correspondants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63261304P 2004-12-01 2004-12-01
US60/632,613 2004-12-01

Publications (2)

Publication Number Publication Date
WO2006060533A2 WO2006060533A2 (fr) 2006-06-08
WO2006060533A3 true WO2006060533A3 (fr) 2007-07-26

Family

ID=36263731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/043409 WO2006060533A2 (fr) 2004-12-01 2005-11-29 Conjugues medicament anticorps et procedes correspondants

Country Status (3)

Country Link
EP (1) EP1817059A2 (fr)
JP (1) JP4993645B2 (fr)
WO (1) WO2006060533A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8562693B2 (en) 2006-03-24 2013-10-22 L'oreal Method of dyeing and lightening keratin materials in the presence of a reducing agent comprising a fluorescent deisulphide dye
US8911732B2 (en) 2010-12-20 2014-12-16 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
US9056910B2 (en) 2012-05-01 2015-06-16 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
US9175089B2 (en) 2012-03-30 2015-11-03 Genentech, Inc. Anti-LGR5 antibodies and immunoconjugates
US9453078B2 (en) 2009-01-12 2016-09-27 Cytomx Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
US20070134243A1 (en) * 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
US7780743B2 (en) 2006-03-24 2010-08-24 L'oreal S.A. Fluorescent entity, dyeing composition containing at least one fluorescent entity, and method for lightening keratin materials using said at least one fluorescent entity
FR2898902B1 (fr) * 2006-03-24 2010-09-10 Oreal Colorants particuliers de type naphtalimide, composition tinctoriale comprenant au moins un tel colorant, procede de mise en oeuvre et utilisations
ATE518916T1 (de) 2006-03-24 2011-08-15 Oreal Färbezusammensetzung mit einem thiol/disulfid- leuchtfarbstoff mit einem heterozyklus und einer internen kationischen ladung sowie verfahren zur aufhellung von keratinmaterial mit diesem farbstoff
US8008316B2 (en) 2006-09-12 2011-08-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Azonafide derived tumor and cancer targeting compounds
CA2692819A1 (fr) 2007-07-16 2009-01-22 Genentech, Inc. Anticorps anti-cd79b humanises, immunoconjugues, et procedes d'utilisation
PE20140614A1 (es) 2007-07-16 2014-05-28 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
FR2921377B1 (fr) 2007-09-21 2009-10-30 Oreal Compose styryl a motif hydroxy(cyclo)alkylamino thiol/disulfure, procede d'eclaircissement des matieres keratiniques a partir de ce colorant
FR2921381B1 (fr) 2007-09-21 2009-10-30 Oreal Colorant hemicyanine styryle thiol/disulfure, composition tinctoriale comprenant ce colorant, procede d'eclaircissement des matieres keratiniques a partir de ce colorant
FR2921376B1 (fr) 2007-09-21 2009-10-30 Oreal Compose styryl tetrahydroquinolinium thiol/disulfure, procede d'eclaircissement des matieres keratiniques a partir de ce colorant
FR2921373B1 (fr) 2007-09-21 2009-10-30 Oreal Colorant derive d'indole styryle a linker alkylene, composition tinctoriale comprenant ce colorant, procede d'eclaircissement des matieres keratiniques a partir de ce colorant
US8119656B2 (en) 2007-12-07 2012-02-21 The Board Of Regents Of The University Of Texas System Inhibitors of the influenza virus non-structural 1 protein
WO2009089537A2 (fr) * 2008-01-11 2009-07-16 Northwestern University Composés anticancéreux
SI2247620T1 (sl) 2008-01-31 2016-09-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
WO2009144205A1 (fr) 2008-05-30 2009-12-03 Basf Se Matières semi-conductrices à base de rylène et leurs procédés de fabrication et d'utilisation
EP2538981B1 (fr) 2010-02-23 2017-12-20 F. Hoffmann-La Roche AG Compositions et procedes de diagnostic et traitement de tumeurs
IN2014DN08841A (fr) * 2012-05-02 2015-05-22 Lubrizol Advanced Mat Inc
EP3925627A1 (fr) 2012-05-15 2021-12-22 Concortis Biosystems, Corp Conjugués de médicaments et leurs utilisations
CA2872327A1 (fr) 2012-05-21 2013-11-28 Genentech, Inc. Anticorps et immunoconjugues anti-ly6e et procedes d'utilisation
BR112015002193A2 (pt) 2012-08-02 2017-07-04 Genentech Inc anticorpos anti-etbr e imunoconjugados
KR20150032886A (ko) 2012-08-02 2015-03-30 제넨테크, 인크. 항-etbr 항체 및 면역접합체
CN103013497A (zh) * 2012-12-21 2013-04-03 武汉大学 一种巯基荧光探针及其制备方法
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
EP3046940B1 (fr) 2013-09-17 2019-07-03 F.Hoffmann-La Roche Ag Procédés d'utilisation d'anticorps anti-lgr5
US9290578B2 (en) 2013-10-21 2016-03-22 Genentech, Inc. Anti-Ly6E antibodies and methods of use
EP3689910A3 (fr) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Procédé d'utilisation d'immunoconjugués anti-cd79b
TWI660741B (zh) 2015-11-03 2019-06-01 財團法人工業技術研究院 抗體藥物複合物及其製造方法
TR201618160A2 (tr) * 2016-12-09 2018-06-21 T C Istanbul Medipol Ueniversitesi Parazi̇ti̇k ve neoplasti̇k hastaliklarin tedavi̇si̇nde kullanima uygun özgün i̇laç molekülleri̇ ve bunlarin hazirlanmasinda kullanilacak usuller
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN107625771B (zh) * 2017-09-27 2018-12-14 徐州玖胜医疗器械有限公司 一种miR-17基因抑制剂及用于治疗胃癌的用途
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN114615999B (zh) 2019-09-05 2024-03-08 法马马有限公司 药物抗体偶联物
EP4138923A1 (fr) 2020-04-21 2023-03-01 Pharma Mar, S.A. Conjugués médicament-anticorps

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005365A1 (fr) * 1993-08-18 1995-02-23 Basf Aktiengesellschaft Nouveaux bis-naphtalimides utilises dans le traitement de cancers
WO1996003384A1 (fr) * 1994-07-22 1996-02-08 Ctrc Research Foundation Bis-naphtalimides avec segments de liaison presentant des heteroatomes et utilisation de ces derniers
US5641782A (en) * 1995-02-16 1997-06-24 The Dupont Merck Pharmaceutical Company 3-aromatic and 3-heteroaromatic substituted bisnaphthalimides
US20030216309A1 (en) * 2001-10-12 2003-11-20 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of ErbB2 and uses therefor

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
DE3707651A1 (de) 1987-03-10 1988-09-22 Knoll Ag Bis-naphthalimide, ihre herstellung und verwendung
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5416089A (en) 1993-06-24 1995-05-16 The Du Pont Merck Pharmaceutical Company Polycyclic and heterocyclic chromophores for bis-imide tumoricidals
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
CA2226575C (fr) 1995-07-27 2011-10-18 Genentech, Inc. Formulation de proteine lyophilisee isotonique et stable
JP3646191B2 (ja) 1996-03-19 2005-05-11 大塚製薬株式会社 ヒト遺伝子
EP1226177B1 (fr) 1999-10-29 2008-07-09 Genentech, Inc. Compositions a base d'anticorps diriges contre l'antigene de cellules souches de la prostate (psca) et procedes d'utilisation associes
JP2003532378A (ja) 1999-11-29 2003-11-05 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク リンパ腫／黒色腫の発症に関与する新規Ｆｃ受容体型黒色腫をコードする５つの新規遺伝子の単離
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001090304A2 (fr) 2000-05-19 2001-11-29 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
CA2420140A1 (fr) 2000-08-24 2002-02-28 Genentech, Inc. Compositions et procedes de diagnostic et traitement de tumeurs
KR20040014392A (ko) 2000-08-24 2004-02-14 제넨테크, 인크. 종양의 진단 및 치료용 조성물 및 방법
MXPA03003151A (es) 2000-10-13 2003-08-19 Eos Biotechnology Inc Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata.
AU2002243495A1 (en) 2001-01-12 2002-07-24 University Of Medicine And Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
AU2002314901A1 (en) 2001-06-04 2002-12-16 Eos Biotechnology, Inc. Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
JP2005501528A (ja) 2001-06-05 2005-01-20 エクセリクシス・インコーポレイテッド ｐ５３経路のモディファイヤーとしてのＧＦＡＴｓおよび使用方法
AU2002347428A1 (en) 2001-06-18 2003-01-02 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2633171C (fr) 2001-06-20 2012-11-20 Genentech, Inc. Compositions et procedes destines au diagnostic et au traitement de tumeurs
WO2003009814A2 (fr) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Nouveaux genes, compositions, trousses et methodes d'identification, evaluation, prevention, et traitement du cancer de la prostate
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
NZ573831A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
WO2003029421A2 (fr) 2001-10-03 2003-04-10 Origene Technologies, Inc. Genes regules du cancer du sein
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN1685055A (zh) 2001-10-31 2005-10-19 爱尔康公司 骨形态发生蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途
WO2003042661A2 (fr) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030134790A1 (en) 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US7317087B2 (en) 2002-03-25 2008-01-08 The Uab Research Foundation Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof
AU2003247576A1 (en) 2002-06-18 2003-12-31 Archemix Corp. Aptamer-toxin molecules and methods for using same
US20040249130A1 (en) 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
KR20050048615A (ko) 2002-08-19 2005-05-24 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
EP1391213A1 (fr) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques
JP2004113151A (ja) 2002-09-27 2004-04-15 Sankyo Co Ltd 癌遺伝子及びその用途
ES2388280T3 (es) 2002-12-20 2012-10-11 Abbott Biotherapeutics Corp. Anticuerpos que reaccionan frente a GPR64 y utilización de los mismos
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
US20050227301A1 (en) 2003-01-10 2005-10-13 Polgen Cell cycle progression proteins
AU2004213432A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Novel therapeutic targets in cancer
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005365A1 (fr) * 1993-08-18 1995-02-23 Basf Aktiengesellschaft Nouveaux bis-naphtalimides utilises dans le traitement de cancers
WO1996003384A1 (fr) * 1994-07-22 1996-02-08 Ctrc Research Foundation Bis-naphtalimides avec segments de liaison presentant des heteroatomes et utilisation de ces derniers
US5641782A (en) * 1995-02-16 1997-06-24 The Dupont Merck Pharmaceutical Company 3-aromatic and 3-heteroaromatic substituted bisnaphthalimides
US20030216309A1 (en) * 2001-10-12 2003-11-20 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of ErbB2 and uses therefor

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAILLY CHRISTIAN ET AL: "Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono- and bisfuronaphthalimides.", BIOCHEMISTRY, vol. 42, no. 14, 15 April 2003 (2003-04-15), pages 4136 - 4150, XP002435351, ISSN: 0006-2960 *
BRANA M F ET AL: "Naphthalimides as anti-cancer agents: Synthesis and biological activity.", CURRENT MEDICINAL CHEMISTRY - ANTI-CANCER AGENTS, vol. 1, no. 3, November 2001 (2001-11-01), pages 237 - 255, XP008079357, ISSN: 1568-0118 *
BRANA M F ET AL: "SYNTHESIS, BIOLOGICAL ACTIVITY, AND QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF AZANAPHTHALIMIDE AND ARYLNAPHTHALIMIDE DERIVATIVES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 47, no. 9, 2004, pages 2236 - 2242, XP008060139, ISSN: 0022-2623 *
BRANA MIGUEL F ET AL: "New analogues of amonafide and elinafide, containing aromatic heterocycles: Synthesis, antitumor activity, molecular modeling, and DNA binding properties.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, no. 6, 11 March 2004 (2004-03-11), pages 1391 - 1399, XP002435350, ISSN: 0022-2623 *
CARRASCO C ET AL: "DNA sequence recognition by bispyrazinonaphthalimides antitumor agents", BIOCHEMISTRY 14 OCT 2003 UNITED STATES, vol. 42, no. 40, 14 October 2003 (2003-10-14), pages 11751 - 11761, XP002435352, ISSN: 0006-2960 *
CHARI R V J ET AL: "IMMUNOCONJUGATES CONTAINING NOVEL MAYTANSINOIDS: PORMISING ANTICANCER DRUGS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 52, no. 1, January 1992 (1992-01-01), pages 127 - 131, XP000453560, ISSN: 0008-5472 *
HARRIS M: "Monoclonal antibodies as therapeutic agents for cancer", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 5, no. 5, May 2004 (2004-05-01), pages 292 - 302, XP004808280, ISSN: 1470-2045 *
SURESH BABU MEKAPATI ET AL: "QSAR OF ANTICANCER COMPOUNDS. BIS(11-OXO-11H-INDENO Ä1,2-BÜQUINOLINE-6-CARBOXAMIDES), BIS(PHENAZINE-1-CARBOXAMIDES), AND BIS(NAPHTHALIMIDES)", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 9, no. 11, 2001, pages 2757 - 2762, XP008060138, ISSN: 0968-0896 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8562693B2 (en) 2006-03-24 2013-10-22 L'oreal Method of dyeing and lightening keratin materials in the presence of a reducing agent comprising a fluorescent deisulphide dye
US8685114B2 (en) 2006-03-24 2014-04-01 L'oreal Composition for dyeing and lightening keratin materials comprising a fluorescent deisulphide dye compound
US9453078B2 (en) 2009-01-12 2016-09-27 Cytomx Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
US8911732B2 (en) 2010-12-20 2014-12-16 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
US9175089B2 (en) 2012-03-30 2015-11-03 Genentech, Inc. Anti-LGR5 antibodies and immunoconjugates
US9056910B2 (en) 2012-05-01 2015-06-16 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
US9597411B2 (en) 2012-05-01 2017-03-21 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates

Also Published As

Publication number Publication date
JP2008521920A (ja) 2008-06-26
EP1817059A2 (fr) 2007-08-15
JP4993645B2 (ja) 2012-08-08
WO2006060533A2 (fr) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2006060533A3 (fr) Conjugues medicament anticorps et procedes correspondants
WO2007064345A3 (fr) Composés de bis-1,8-naphtalimide substitués par un groupe hétérocyclique, conjugués anticorps-médicament et procédés d'utilisation de ceux-ci
WO2008076333A8 (fr) Polymères à base de cyclodextrine pour administration d'agents thérapeutiques
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
WO2005117986A3 (fr) Conjugues de medicaments anticorps et procedes correspondants
CY1114941T1 (el) Πολυμερη βασιζομενα σε κυκλοδεξτρινη για χορηγηση των θεραπευτικων μεσων που ειναι ομοιοπολικως δεσμευμενα σε αυτα
WO2009016410A3 (fr) Composés chimiques 831
WO2005072061A3 (fr) Remedes conjugues de therapie et diagnostic du cancer
WO2007100385A3 (fr) Conjugués anticorps-médicaments à base de depsipeptide macrocyclique et méthodes associées
WO2009016516A8 (fr) Agents cytotoxiques comprenant de nouveaux dérivés de la tomaymycine et leur utilisation thérapeutique
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
NZ600039A (en) Biocompatible biodegradable fumagillin analog conjugates
WO2005116002A3 (fr) Inhibiteurs de deshydrogenase 1-beta-hydroxy steroide de type 1
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
WO2007100905A3 (fr) Conjugués de polymères contenant de l'acryloyloxyéthylphosphorylcholine et leur préparation
HK1102991A1 (en) Pharmaceutical formulation of decitabine
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
RS20080002A (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
WO2007106544A3 (fr) Conjugues de chelation presentant une fraction aromatique substituee et leurs derives
HK1123728A1 (en) Immuno-rna-constructs
PL1727817T3 (pl) Pochodne azabicyklooktan-3-onu i ich zastosowanie
WO2007056236A3 (fr) Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides administree par voie intraveineuse
NZ593438A (en) Synthesis of polymer conjugates of indolocarbazole compounds
WO2005002516A3 (fr) Conjugues peptides-medicaments integres dans des leucocytes
WO2005041881A3 (fr) Conjugues taxoide/acide gras et preparations les contenant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007544495

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005852595

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005852595

Country of ref document: EP